Exploring the frontier of cardiovascular pharmacotherapy.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 968, doi. 10.1002/phar.2645
- By:
- Publication type:
- Article
Works matching IS 02770008 AND DT 2021 AND VI 41 AND IP 12
Results: 13
1
2
Current pharmacotherapy management of children and adults with pericarditis: Prospectus for improved outcomes.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 1041, doi. 10.1002/phar.2640
- By:
- Publication type:
- Article
3
Chemotherapy‐associated cardiomyopathy: Mechanisms of toxicity and cardioprotective strategies.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 1066, doi. 10.1002/phar.2638
- By:
- Publication type:
- Article
4
Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 998, doi. 10.1002/phar.2633
- By:
- Publication type:
- Article
5
Comparison of risk‐scoring systems for heparin‐induced thrombocytopenia in cardiac surgery patients.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 1033, doi. 10.1002/phar.2636
- By:
- Publication type:
- Article
6
Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 1081, doi. 10.1002/phar.2639
- Publication type:
- Article
7
Meta‐analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 1009, doi. 10.1002/phar.2635
- By:
- Publication type:
- Article
8
NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo‐DHF trial.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 978, doi. 10.1002/phar.2626
- By:
- Publication type:
- Article
9
Renin‐angiotensin‐aldosterone system inhibitors and major cardiovascular events and acute kidney injury in patients with coronary artery disease.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 988, doi. 10.1002/phar.2624
- By:
- Publication type:
- Article
10
Omega‐3 fatty acids for the prevention of atherosclerotic cardiovascular disease.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 1056, doi. 10.1002/phar.2615
- By:
- Publication type:
- Article
11
Effects of aging on clinical outcomes in patients receiving genotype‐guided P2Y12 inhibitor selection after percutaneous coronary intervention.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 970, doi. 10.1002/phar.2611
- By:
- Publication type:
- Article
12
Issue Information.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 965, doi. 10.1002/phar.2294
- Publication type:
- Article
13
Pre‐transplant amiodarone use does not affect long‐term heart transplant survival.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 12, p. 1024, doi. 10.1002/phar.2533
- By:
- Publication type:
- Article